PDGFRB and neoplasm: Sunitinib achieved its inhibitory effect on tumor angiogenesis mainly by blocking VEGFR and PDGFR [29, 30], which results in a significant longer progression free survival (11 versus 5 months, p < 0.001) and overall survival (26.4 versus 21.8 months, p = 0.049) compared to interferon alpha (IFN-α) therapy [31].